Research
Hormonal
Semaglutide 2.4 mg administered once weekly via subcutaneous injection significantly reduces body weight in adults with obesity or overweight when used as an adjunct to lifestyle modifications.
If you have obesity or overweight with a related health condition, ask your doctor about Semaglutide 2.4 mg. It is taken as a once-weekly injection alongside diet and exercise. Expect significant weight loss (around 15% in trials), but be prepared for temporary stomach issues like nausea, which usually get better over time.
StrongSupportsVERY_HIGH confidence
A weekly dosage of 2.4 mg of semaglutide and lifestyle intervention significantly decreased body weight. The mean change from baseline to week 68 was significantly higher in the semaglutide group (14.9%) as compared to placebo (2.4%) (P<0.001).
Why this rating
Based on multiple high-citation Phase 3 randomized clinical trials and guidelines.
Source
An Update on Semaglutide Research: A Bibliometric Analysis and a Literature Review
Namrata Dagli et al. · Cureus · 2023
DOI 10.7759/cureus.46510
narrative_reviewCited 8×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- Semaglutide improves cardiovascular outcomes, including reducing the risk of major adverse cardiovascular events (MACE), in patients with type 2 diabetes.Strong
- Semaglutide promotes resolution of non-alcoholic steatohepatitis (NASH) without worsening liver fibrosis in patients with NASH and liver fibrosis.Good
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →